Disturbed permanent tooth eruption is common in cleidocranial dysplasia (CCD), a skeletal disorder caused by heterozygous mutation of RUNX2, but the mechanism underlying is still unclear. As it is well known that dental follicle cells (DFCs) play a critical role in tooth eruption, the changed biological characteristics of DFCs might give rise to disturbance of permanent tooth eruption in CCD patients. Thus, primary DFCs from one CCD patient and normal controls were collected to investigate the effect of RUNX2 mutation on the bone remodeling activity of DFCs and explore the mechanism of impaired permanent tooth eruption in this disease. Conservation and secondary structure analysis revealed that the RUNX2 mutation (c.514delT, p.172fs) found in the present CCD patient was located in the highly conserved RUNT domain and converted the structure of RUNX2. After osteogenic induction, we found that the mineralised capacity of DFCs and the expression of osteoblast-related genes, including RUNX2, ALP, OSX, OCN and Col Iα1, in DFCs was severely interfered by the RUNX2 mutation found in CCD patients. To investigate whether the osteogenic deficiency of DFCs from the CCD patient can be rescued by RUNX2 restoration, we performed 'rescue' experiments. Surprisingly, the osteogenic deficiency and the abnormal expression of osteoblast-associated genes in DFCs from the CCD patient were almost rescued by overexpression of wild-type RUNX2 using lentivirus. All these findings indicate that RUNX2 mutation can reduce the osteogenic capacity of DFCs through inhibiting osteoblast-associated genes, thereby disturbing alveolar bone formation, which serves as a motive force for tooth eruption. This effect may provide valuable explanations and implications for the mechanism of delayed permanent tooth eruption in CCD patients.
Introduction
Runt-related transcription factor-2 (RUNX2) is a member of RUNX family located on chromosome 6p21 and is essential for osteoblast differentiation and skeletal morphogenesis (1, 2) . As a master transcriptional factor involved in bone formation, RUNX2 is crucial for both intramembranous and endochondral ossification (3, 4) . RUNX2 is continuously expressed throughout intramembranous ossification. While RUNX2 expression is restricted to those cells located at peripheral mesenchymal condensations during endochondral ossification (5) . RUNX2 null (RUNX2 -/-) mice died just after birth and absolutely failed in bone formation, whereas the development of cartilage was nearly normal (1, 6) . In addition, another verified key role of RUNX2 in osteoblast differentiation is that RUNX2 can regulate the expression of several osteoblast marker genes, including osterix (OSX), osteocalcin (OCN), bone sialoprotein (BSP), osteopontin (OPN) and collagen I (Col I) (5, (7) (8) (9) (10) (11) .
RUNX2 mutation is responsible for cleidocranial dysplasia (CCD; MIM 119600), a rare autosomal dominant skeletal disorder (12, 13) . The primary clinical features of CCD are mainly manifested in the bone and teeth, including aplastic or hypoplastic clavicles, persistently open or delayed closing of fontanelle, distal phalanx dysplasia, short stature and multiple dental anomalies such as supernumerary teeth, retention of primary dentition and delayed eruption of permanent teeth (14, 15) . However, the phenotypic spectrum differs dramatically among CCD patients and those abnormalities are not observed in all individuals (14, 16) . Despite the numerous skeletal deficiencies observed in CCD individuals, the dental anomalies are usually their main complaints, especially for impaired permanent tooth eruption (17) .
Tooth eruption is a fundamental developmental and physiological process, which requires both bone resorption and bone formation (18, 19) . During tooth eruption, bone resorption promotes the formation of tooth eruption pathway, while bone formation serves as an eruption force to propel the tooth out of its bony crypt (20) . It had been widely accepted that the dental follicle, a loose connective tissue sac between the alveolar bone of the socket and the enamel organ of the unerupted tooth, is crucial for tooth eruption (21, 22) . The reason is that the dental follicle can regulate the required osteoclastogenesis and osteogenesis for tooth emergence (19, 20) . While it is noted that dental follicle cells (DFCs) are precursors of alveolar osteoblasts and can differentiate into the alveolar bone and the mineralised bone-like cementum (19, 23, 24) . Therefore, DFCs participate in tooth eruption not only as a regulator of bone remodelling but also as the precursors of alveolar osteoblasts which are critical for bone formation during tooth eruption.
Recently, we reported a frameshift mutation of RUNX2 in a Chinese CCD patient who is receiving treatment at our hospital for impacted permanent teeth. Our previous studies showed that this RUNX2 mutation reduced the osteoclast-inductive capacity of DFCs and restricted the formation of tooth eruption pathway (25) . However, the effect of RUNX2 mutation on the eruption force of permanent tooth is still unknown. In this study, primary DFCs from the CCD patient and normal controls were extracted to explore the effect of RUNX2 mutation on the osteogenic capacity of DFCs and a rescue assay was performed to verify the conclusions we got.
Materials and Methods

Participants
A 16-year-old boy, clinically and genetically diagnosed with CCD (16) , and three unaffected children (aged 12-16 years) were included in the present study. This study was ethically approved by the Ethical Committee of Peking University School of Stomatology (approval No. PKUSSIRB-2012004). The methods were carried out in accordance with the relevant guidelines, including any relevant details. All the experiments in this study were carried out with informed consent.
Conservation and secondary structural analysis
Conservation analysis of the affected amino acids among nine species was performed using the Homologene database library (http://www. ncbi.nlm.nih.gov/homologene). Secondary structure of wild-type RUNX2 (WT-RUNX2) and mutant RUNX2 were predicted by PsiPred 3.3 (http://bioinf.cs.ucl.ac.uk/psipred).
Cell culture
Dental follicles were collected during exposure of impacted mandibular premolars for treatment. To obtain single DFCs suspension, dental follicles were digested in 0.3% collagenase type I (Sigma-Aldrich, MO, USA) for 40 min at 37°C. Then, the cells were cultured in a proliferation medium (PM) containing DMEM (Gibco, NY, USA), 10% fetal bovine serum (Gibco), 100 U/ml penicillin (Gibco), and 100 µg/ml streptomycin (Gibco) in an incubator at 37°C with 5% CO2. DFCs between 3-5 passages were used in subsequent experiments.
Mutation analysis
To detect RUNX2 status in DFCs from the CCD patient and normal control, we extracted DNA from DFCs with a General AllGen Kit (Cwbiotech, Beijing, China) according to the manufacturer's protocol. Exon 2 of RUNX2 gene was amplified by polymerase chain reaction (PCR), and the PCR products were then sequenced with an ABI 3730 sequencer.
Immunohistochemistry
For immunohistochemistry staining, DFCs seeded on coverslips were fixed in 4% paraformaldehyde (Sigma-Aldrich) for 20 min, permeated with 0.3% Triton X-100 (Sigma-Aldrich) for 10 min, blocked in bovine serum, and incubated with primary antibodies against vimentin (Zhongshan Bioengineering Co. Ltd., Beijing, China) or cytokeratin (Zhongshan Bioengineering Co. Ltd.) at 4°C overnight. The SP immunohistochemistry kit was used with a 3, 3′-diaminobenzidine colouration kit (Zhongshan Bioengineering Co. Ltd.) according to the instruction of the manufacturer. The results were observed with a light microscope equipped with a camera (Carl Zeiss, TH, Germany).
Lentivirus construction and establishment of stably infected DFCs
The full-length human WT-RUNX2 cDNA was subcloned with EcoR I and BamH I (NEB, MA, USA) into the pHBLV-CMVIEZsGreen-T2A-puro vector to generate lentivirus overexpressing WT-RUNX2. Lentivirus containing a green fluorescent protein (GFP) tag with no target gene was used as the negative control. The recombinant and control vectors were transfected, along with the packaging vectors psPAX2 and pMD2.G into 293T cells to produce lentivirus. The supernatant was harvested, filtered, and concentrated at 2 days post-transfection. To establish stable overexpression of human WT-RUNX2 or negative control (GFP control) in DFCs, lentivirus (multiplicity of infection = 100) mixed with 10 ug/ml polybrene (Sigma) were used to infect the second passage of DFCs for 12 h. Then, the medium was refreshed, and DFCs were incubated for another 48 h. Infected cells were selected in the presence of 1 ug/ml puromycin (Sigma) for 7 days. Cells were observed under a fluorescent microscope to identify their infection efficiency. Real-time PCR and western blotting were used to detect the expression of RUNX2 in surviving cells after puromycin selection.
Osteogenic differentiation
For osteogenic induction, DFCs were seeded with a density of 1 × 105 cells/well in 6-well plates. When 80% confluence was reached, the PM was changed to osteogenic medium (OM) consisting of 100 nM/l dexamethasone (Sigma-Aldrich), 10 mM/l β-glycerophosphate (Sigma-Aldrich), and 50 µg/ml L-ascorbic acid (Sigma-Aldrich) in addition to the PM.
ALP activity test, ALP staining and alizarin red staining
After DFCs were cultured in PM or OM for 7 or 14 days, alkaline phosphatase (ALP) activity was analysed using the ALP Activity Assay kit (Jiancheng, Nanjing, China). Total protein was determined with the BCA method using the Pierce protein assay kit (Thermo Fisher, MA, USA). ALP activity relative to the control treatment was calculated after normalisation to total protein content. ALP staining was analysed with the ALP histochemical staining kit (Cwbiotech) after induction for 14 days in the OM. For alizarin red staining, after induction for 21 days in OM, DFCs were fixed with 4% paraformaldehyde and incubated with 2% alizarin red (Sigma-Aldrich) for 20 min. The image of ALP staining and alizarin red staining were captured by the scanner (HP, USA).
Real-time PCR
After DFCs were cultured in OM or PM for 14 days, total RNA was extracted with Trizol reagent (Invitrogen, CA, USA), and reversely transcribed into cDNA with a reverse transcription kit (Thermo Fisher). Real-time PCR was performed using the SYBR Green PCR kit (Roche Applied Science, IN, USA) on the ABI 7500 Real-Time PCR System (Applied Biosystems, CA, USA). The relative mRNA levels were normalised to the expression of GAPDH.
Western blotting analysis
After DFCs were cultured in OM or PM for 14 days, the total protein was extracted using the RIPA kit (Huaxing bio, Beijing, China). Protein concentration was tested with the Pierce protein assay kit (Thermo Fisher). The lysate was electrophoresed in 10% SDS-PAGE gels and transferred to PVDF membranes (Millipore, MA, USA). After being blocked in 5% skim milk, membranes were incubated with primary antibodies against RUNX2 (CST, MA, USA), ALP (Huaxing bio), OSX (Abcam, Cambridge, UK), Col Iα1 (Abcam) and OCN (Abcam). HRP-conjugated secondary antibody (Jackson ImmunoResearch, PA, USA) was then used. The immune-reactive bands were visualised by the enhanced chemiluminescence blotting kit (Cwbiotech). Blots against GAPDH served as a loading control.
Statistical analysis
All the experiments were repeated at least three times independently. All data was presented as the mean ± SD. Group mean values were compared, as appropriate, by Student's two-tailed t-test or one-way ANOVA with Schefe's post-hoc test. P < 0.05 was considered as statistically significant.
Results
Clinical manifestation of the CCD patient
This patient was a familial case, and his father was also affected. The proband showed typical CCD phenotypes, including delayed closure of sagittal suture ( Figure 1A and B), hypoplastic clavicles ( Figure 1C) , and classic dental abnormalities. The skull anteroposterior radiographs and chest radiograph of the patient had been shown in the previous papers of our research group (16, 26) . Panoramic radiological and clinical examination showed that four deciduous teeth were still retained, and their successors were impacted in the alveolar bones, though the CCD patient was already 16 years old ( Figure 1D-G) . In addition, nine supernumerary teeth were present in the alveolar bones ( Figure 1D ). Surgical exposure combined with orthodontic traction was applied on this patient and dental follicle tissues were collected during surgical exposure of the impacted canines and premolars ( Figure 1H ).
RUNX2 mutation analysis
Our previous study found a frameshift mutation (c.514delT, p.172fs) in the exon 2 of RUNX2 in this patient (Figure 2A) , which further confirmed the clinical diagnosis of CCD (15) . Conservation analysis among nine species showed that the affected residues in RUNX2 have a high level of evolutionary conservation among different species ( Figure 2B ). The secondary structure analysis showed that the RUNX2 mutation resulted in transformations of RUNX2 protein structure, and the changes were mainly located in the RUNT domain ( Figure 2C ). Mutation of the conserved residues and the changes of secondary structure may affect the function of the RUNX2 protein.
RUNX2 mutation reduces the expression of RUNX2 in DFCs
The effect of this RUNX2 mutation on the biological characterisation of DFCs was explored using primary DFCs isolated from the CCD patient (named as CCD-DFCs). Primary DFCs extracted from three gender-and age-matched normal participants were used as controls (named as CON-DFCs). Immunohistochemical staining was performed to examine the source of the cultured cells. CCDDFCs and CON-DFCs were vimentin-positive and keratin-negative ( Figure 3A) , indicating that these cells were derived from mesenchymal cells. The morphology of CCD-DFCs and CON-DFCs were both similar with spindle-shaped like typical fibroblasts. The frameshift mutation of RUNX2 (c.514delT, p.172fs) was confirmed by Sanger sequencing with DNA from CCD-DFCs ( Figure 3B ), which was consistent with the result using blood samples in our previous study (16) . The effect of the detected RUNX2 mutation on RUNX2 expression was then investigated. RUNX2 mRNA level was reduced more than 50% by RUNX2 mutation (P < 0.05) ( Figure 3B ). Western blotting result showed that RUNX2 expression at the protein level was significantly reduced by the RUNX2 mutation ( Figure 3C ).
RUNX2 mutation interferes with the osteogenic ability of DFCs
DFCs are multipotent mesenchymal stem cells, which can differentiate into osteoblasts, adipocytes, chondrocytes, and neural cells under different in vitro conditions (19, 23, 24) . In the present study, the effect of RUNX2 mutation on the osteogenic differentiation of DFCs was explored. As ALP is considered to be an early marker of mineralisation, the effect of RUNX2 mutation on the ALP activity of DFCs was first tested. We found that ALP activity of the CON-DFCs increased approximately 1.2-to 1.5-fold after osteogenic induction for 7 days or 14 days (P < 0.05) ( Figure 4A and B) . ALP activity was reduced 60%-80% by the RUNX2 mutation compared to the normal control whether under osteogenic induction or not (P < 0.05) ( Figure 4A and B) . ALP staining showed that ALP expression in the CCD-DFCs was lower than that of the control in the basal condition, and the difference was much clearer after osteogenic induction ( Figure 4C) , showing a similar result with ALP activity. Alizarin red staining revealed that mineralised nodules in CCD-DFCs were obviously fewer than the normal control after osteogenic induction for 21 days (Figure 4D ), indicating reduced mineralisation in CCD patients.
The effect of RUNX2 mutation on the expression of osteoblastspecific genes was thereafter evaluated. The mRNA level of RUNX2 in DFCs was decreased approximately 50% by the RUNX2 mutation both in basal and osteogenic media found in the CCD group (P < 0.05) ( Figure 4E ). Consistently, the mRNA level of osteogenic markers, such as ALP, OSX, OCN and Col Iα1, was reduced 20-70% by the RUNX2 mutation (P < 0.05) (Figure 4F-I) . Western blotting results indicated that the protein level of RUNX2, Col Iα1, ALP, OSX and OCN in CCD-DFCs was significantly decreased compared with the normal control in both basal and osteogenic media ( Figure 4J ).
Overexpression of WT-RUNX2 restores the expression of RUNX2 in DFCs from CCD patient
Our above-mentioned data showed that RUNX2 mutation reduced RUNX2 expression and interfered with the osteogenic ability of DFCs. To investigate whether recovering RUNX2 expression in CCD-DFCs would rescue the osteogenic deficiency of DFCs caused by RUNX2 mutation, we constructed lentivirus that expresses full-length WT-RUNX2 with a GFP tag and infected CCD-DFCs. A lentivirus carrying a GFP tag without the target gene was used as control. The results showed that GFP expression was observed in more than 90% of the stably infected DFCs under fluorescent microscopy in all groups ( Figure 5A ). RUNX2 mRNA level was increased 5-fold in CCD DFCs stably infected with WT-RUNX2 (P < 0.05) ( Figure 5B ). Consistently, western blot results showed that overexpression of WT-RUNX2 in CCD-DFCs restored the reduced RUNX2 expression caused by RUNX2 mutation ( Figure 5C ). These results indicated that the reduced RUNX2 expression caused by RUNX2 mutation was successfully rescued by infection of WT-RUNX2 using lentivirus.
RUNX2 restoration rescues the reduced mineralisation of DFCs caused by RUNX2 mutation
The effect of RUNX2 restoration on the mineralised deficiency of DFCs caused by RUNX2 mutation was investigated using the above-mentioned stably infected cells. ALP activity test revealed that ALP activity was decreased 70-90% by RUNX2 mutation under basal or osteogenic conditions (P < 0.05) ( Figure 6A and B) . Overexpression of WT-RUNX2 in CCD-DFCs resulted in a 1.5-to 7-fold increase in ALP activity compared to the CCD-DFCs infected with GFP control, whether under osteogenic induction or not (P < 0.05) ( Figure 6A and B) . Notably, ALP activity in CCDDFCs infected with WT-RUNX2 was almost increased to the level of the normal control after osteogenic induction for 14 days ( Figure 6B) . Similarly, ALP staining results showed a lower ALP expression in CCD-DFCs, while this reduction was significantly rescued after infection of WT-RUNX2, especially under osteogenic condition ( Figure 6C ). Alizarin red staining results presented a similar trend as ALP staining that overexpression of WT-RUNX2 noticeably rescued the decreased mineralised nodules in CCD-DFCs after osteogenic induction for 21 days ( Figure 6D ). These results indicated that 
RUNX2 restoration rescues the abnormal expression of osteoblast-associated genes caused by RUNX2 mutation in DFCs
The effect of RUNX2 restoration on the expression of osteoblastassociated genes was further explored using stably transfected cells.
RUNX2 mRNA level was reduced 20-40% by RUNX2 mutation in both basal and osteogenic conditions (P < 0.05) (Figure 7A ), which was consistent with the data shown in Figure 4 . RUNX2 expression in CCD-DFCs was increased more than 4-fold by overexpression of WT-RUNX2 whether under osteogenic induction or not (P < 0.05) ( Figure 7A) . Consistently, the expression of osteogenic markers, such as ALP, OSX, OCN and Col Iα1, was increased 1.3-to 3.5-fold by overexpression of WT-RUNX2 in CCD-DFCs after osteogenic induction for 14 days (P < 0.05) ( Figure 7B-E) , indicating the induction effect of RUNX2 on the expression of the above-mentioned genes.
Western blotting results indicated that the protein level of RUNX2 was reduced in CCD-DFCs compared to CON-DFCs ( Figure 7F ). And a similar pattern was found in the protein level of Col Iα1, ALP, OSX and OCN when RUNX2 was abnormal. Consistently, overexpression of WT-RUNX2 apparently increased the protein level of RUNX2, Col Iα1, ALP, OSX and OCN, especially under osteogenic condition ( Figure 7F ), indicating the rescue effect of RUNX2 restoration on the expression of these key osteoblast-associated genes.
Discussion
In this study we presented a CCD patient with typical CCD features, including delayed eruption of permanent teeth. The RUNX2 heterozygous mutation (c.514delT, p.172fs) found in the CCD patient interfered with the osteogenic capacity and expression of osteoblastspecific genes in DFCs. Restoration of RUNX2 in CCD-DFCs partially rescued the mineralised deficiency of CCD-DFCs. The abnormal expression of osteoblast-associated genes caused by RUNX2 mutation was also restored by overexpression of WT-RUNX2 both at mRNA and protein level. All the results illustrated that RUNX2 mutation reduced osteogenic capacity of DFCs through inhibiting osteoblast-associated genes, therefore interfering with bone formation and the motive force for tooth eruption.
The RUNT domain of RUNX2 protein is a characteristic and highly conserved motif, which is mainly responsible for DNAbinding to the promoters of its downstream target genes and heterodimerisation with core binding factor β (CBFβ) (27) . Though CBFβ does not bind DNA directly, it enhances the DNA binding capacity of RUNX2 protein. The RUNX2 mutation found in the present CCD patient is located in the RUNT domain, and the conservation analysis showed that the affected residues are highly conserved among different species, indicating this mutation may disturb the binding ability of RUNX2. It has been revealed that protein structure is a decisive factor for its function, and transformation of protein structure may lead to destruction of the protein function (28) . The secondary structural analysis showed that the 172fs mutation altered the RUNT domain secondary structure of RUNX2 protein, indicating that this mutation may affect the heterodimerisation activity between RUNX2 and CBFβ and impair subsequent DNA binding and transactivation ability.
RUNX2 is known for its diversified function in different tissues. RUNX2 has been reported to be constitutively expressed in differentiated DFCs whether under osteogenic induction or not (29, 30) . In the present study, we found that RUNX2 expression in DFCs was decreased by the RUNX2 mutation found in the CCD patient. This can be explained that the frameshift mutation found in the CCD patient produced a premature protein truncated at the RUNT domain with only 174 amino acid residues, and the truncated proteins may be unstable and can be degraded rapidly (31) . We also found that the expression of osteoblast-related genes, including ALP, OCN and Col Iα1 was reduced compared to the normal control when RUNX2 mutation was present in DFCs. This was because the osteoblast-specific element 2 (OSE2), the core binding factor site of RUNX2 protein, was present in the promoter region of the above-mentioned osteoblastspecific genes (32) . And RUNX2 mutation can significantly reduce the transactivation ability of RUNX2 on OSE2 (15, 33) . Therefore, it can be speculated that RUNX2 mutation found in the CCD patient reduced the mineralisation capacity of DFCs by downregulating its downstream osteogenic associated genes directly.
Tooth eruption is a localised event that requires chronologically and spatially specific bone remodelling regulated by the dental follicle that surrounds the unerupted tooth (19) . Alveolar bone resorption at the coronal area of tooth bulb is indispensable for the formation of tooth eruption pathway, and the tooth can move through this pathway. Many studies have shown that alveolar bone growth at the base of the crypt serves as the major motive force to propel the tooth through its eruption pathway (20, 34, 35) . Scanning electron microscopy (SEM) studies demonstrated active bone formation at the base of the crypt in the erupting mandibular molars of rats (36) . It has been determined that DFCs exhibit pluripotency in being able to differentiate to alveolar osteoblasts and participate in bone formation during tooth eruption (20, 23, 24) . Previous studies showed that if bone formation was blocked in the local region, an eruption pathway was normally formed but the tooth was still impacted for a lack of eruption force (35, 37, 38) . Based on these studies, our data showed that RUNX2 mutation significantly decreased the mineralisation ability of CCD-DFCs, which may lead to the deficiency of motive force for the unerupted tooth, causing delayed permanent tooth eruption in CCD patients. To investigate whether the osteogenic deficiency of CCD-DFCs can be rescued by restoration of RUNX2 expression, we performed 'rescue' experiments. Our result showed that recovery of RUNX2 expression in CCD-DFCs restored the mineralised deficiency and the abnormal expression of RUNX2 downstream molecules, such as ALP, OSX, OCN and Col Iα1. This is in accordance with a previous study which reported that RUNX2 plays critical roles in the osteogenic differentiation of DFCs by regulating expression of osteogenic markers (23) . Overexpression of RUNX2 in DFCs could increase the expression levels of OPN, Col I, OCN and BSP, and enhance the mineralisation of DFCs (23) . These findings provided sufficient evidence for the fact that RUNX2 mutation is the cause of the reduced osteogenic differentiation of CCD-DFCs and indicated that RUNX2 is essential for alveolar bone growth during tooth eruption. Our data also inspired that RUNX2 is likely to be a target gene for therapy of delayed permanent tooth eruption in CCD patients.
In summary, this study suggests that RUNX2 mutation inhibits the expression of osteoblast-specific genes in DFCs, such as RUNX2, ALP, OSX, OCN and Col Iα1, thereafter interfering with osteogenic capacity of DFCs. This effect restricts alveolar bone formation at the base of tooth crypt, which serves as an eruption force to propel the tooth out of its bony crypt. Our findings provide valuable explanations and implications for the mechanism of delayed permanent tooth eruption in CCD patients.
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